Key facts
- It has raised $8.5M; the latest was Early Stage VC ($8.5M) in Dec 2025.
- Notable investors include YuanBio Venture Capital, Tsinghua Innovation Ventures, Beishang Capital Management (Beijing), Flyfot Ventures, Zero2IPO Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Hailai Technology
- ·The full record, as it builds
Funding rounds
No funding rounds for Hailai Technology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hailai Technology
Manufacturer of advanced biopharmaceuticals intended to create innovative antibody drugs for the treatment of cancer, metabolic disorders, and autoimmune diseases. The company offers proprietary bispecific and multispecific antibody technologies, enabling global pharmaceutical enterprises to access novel therapeutics with enhanced efficacy and competitive differentiation.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Hailai Technology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hailai Technology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hailai Technology in its N-PORT filings yet. We sweep new filings monthly.